Celcuity Inc CELC

$64.37 +0.20 (0.31%)

Valuation

Market cap
3,162,240,000
Revenue TTM
$0
Net income TTM
$-177,040,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
646,400
Avg volume
1,336,656
Day's range
$61.71 – $64.60
Shares out
49,126,000
Stochastic %K
30%
Beta
0.16
Analysts
Strong Buy
Price target
$152.00

Price

Company profile

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients wi...

Show more

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.

Industry
Biotechnology
Sector
Healthcare
Phone
(763) 392-0123
Website
https://www.celcuity.com
Address
2800 Campus Drive, Suite 140, Minneapolis, United States

Latest news

Stocktwits

CharlieeMungerTWITS Nov 16, 2:11 AM
$CELC The latest reported short interest was 10.30 million shares as of October 30, or 24.29% of the float, up just 0.5% from the prior report. This represents potential short-squeeze fuel, not evidence that a squeeze has begun. No newly verified material REVTORPYK sales acceleration, earnings surprise, analyst revision, or regulatory decision emerged since the previous review. The November 9 FDA acceptance remains the latest significant regulatory development. The next meaningful signals would be a high-volume recovery above $70–$73, a decisive close below $63, or measurable commercial sales acceleration.
0 replies
jacobberkstein2 Nov 16, 1:26 AM
$CELC $PGEN 2 good bios to long rn. No flashy high returns but do believe they will succeed in the future slow and steadily. Pgen is safer than celc though
0 replies
Dragonland Nov 12, 8:46 PM
$CELC Another day of biotech carnage and celc holding up
0 replies
huyck1 Nov 12, 5:02 PM
$CELC Pending inflection points for CELC (chronological): - Sales data (Q1) - Permanent reimbursement J-code (Q1) - Overall survival data from Victoria-1 study (Q2) - FDA decision for PIK3CA-mutant disease (June 25 PDUFA) - Mutant-cohort publication and possible guideline expansion (Q2+) - OUS approvals, OUS licensing (Q4+) - Randomized prostate-cancer Phase 2 initiation (Q2+) - First-line breast-cancer Phase 3 (late '28)
2 replies
chartistmind Nov 11, 8:49 PM
$CELC $SPY you didn’t show any appreciation for what i did for you. None whatsoever. Now i’ll leave you to the shorts.
0 replies
Street_secrets Nov 11, 6:00 PM
$CELC I'm very confident... bought more
0 replies
Florestan Nov 11, 11:00 AM
$CELC the "competition" are a bunch of me-toos with "theoretical benefits" which are shitting the bed left and right when they finally read out their data. Lol.
1 replies
Florestan Nov 11, 11:00 AM
$CELC this is obviously a very strong launch, with a very strong drug, with excellent demand. This is a 140 dollar stock right now, minimum. When it rains it pours, but eventually common sense will prevail.
1 replies